Form 4: Protagonist Therapeutics CFO Receives Equity Grants

Protagonist Therapeutics' CFO, Asif Ali, was granted 25,600 restricted stock units and options for 32,000 shares of common stock.

Summary

• Asif Ali, Chief Financial Officer of Protagonist Therapeutics, Inc. (PTGX), acquired 25,600 shares of common stock in the form of restricted stock units (RSUs) on January 2, 2026.
• These RSUs were granted at a price of $0 and will vest in four equal annual installments on January 15, 2027, 2028, 2029, and 2030, contingent on continued service.
• Following this transaction, Asif Ali beneficially owns 86,665 shares of common stock.
• Additionally, Asif Ali was granted stock options to purchase 32,000 shares of common stock on January 2, 2026.
• The stock options have an exercise price of $87.18 per share and an expiration date of January 2, 2036.
• These stock options will vest in 48 equal monthly installments following January 2, 2026, also subject to continued service.
• Following this transaction, Asif Ali beneficially owns 32,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports routine executive compensation in the form of equity grants. This is generally positive as it aligns management's interests with shareholders, but it does not reflect direct operational or financial performance, hence a moderately positive score.

Positives

• The equity grants align the Chief Financial Officer's interests with long-term shareholder value, promoting retention and performance.
• The grants represent a significant component of executive compensation, incentivizing the CFO to contribute to the company's growth and success.

Negatives

• The value of the grants is contingent on the future performance of Protagonist Therapeutics' stock price.
• The vesting schedules mean the full benefit of these grants is not immediately realized and is dependent on continued employment.

Risks

• The value of the restricted stock units and stock options is subject to market fluctuations of Protagonist Therapeutics' common stock.
• Vesting of both the RSUs and stock options is conditional upon the Reporting Person's continued service to the Issuer through each applicable vesting date, posing a risk of forfeiture if employment ceases.

Future Outlook

The equity grants provide a long-term incentive for the Chief Financial Officer, aligning their financial interests with the future performance and growth of Protagonist Therapeutics. The vesting schedules encourage continued service and contribution to the company's strategic objectives over several years.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key executives. These grants are designed to align management's incentives with long-term shareholder value creation, a common strategy across the sector.

Comparison to Industry Standards

• The structure of these equity grants, involving both RSUs and stock options with multi-year vesting schedules, is consistent with typical executive compensation packages observed in comparable biotech companies.
• The grant of RSUs at a $0 price is standard for compensation, representing a direct equity award, while stock options with an exercise price reflect a future potential gain tied to stock appreciation, similar to practices at companies like Regeneron Pharmaceuticals or Vertex Pharmaceuticals for their executive teams.

Corporate Governance

Stakeholder Impact

• Shareholders: The grants align the CFO's financial incentives with the company's long-term stock performance, potentially benefiting shareholders through motivated leadership.
• Employees (CFO): Asif Ali receives significant equity compensation, providing a substantial incentive for continued service and performance.

Next Steps

• Asif Ali's continued service to Protagonist Therapeutics is required for the vesting of both the restricted stock units and stock options.
• The company will continue to report any changes in beneficial ownership by insiders as required by SEC regulations.

Key Dates

Recommendation

This Form 4 reports routine equity compensation grants to the Chief Financial Officer, which is a standard practice to align executive interests with long-term shareholder value. It does not contain information that would significantly alter the investment thesis for Protagonist Therapeutics, hence a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Protagonist Therapeutics, PTGX, Asif Ali, CFO, Form 4, SEC filing, equity grant, restricted stock units, stock options, insider transaction, executive compensation